A five-year clinical trial reveals that fenofibrate significantly increases levels of the metabolic hormone FGF21, prompting questions about its role in ageing and cardiovascular health among people with type 2 diabetes.
A five-year randomised trial has found that fenofibrate, a cholesterol-lowering drug used in type 2 diabetes, markedly increases circulating fibroblast growth factor 21, or FGF21, a hormone linked in laboratory studies to metabolic regulation and ageing. The findings, published in The Journal of Clinical Endocrinology & Metabolism and indexed on PubMed, come from a subgroup analysis of the long-running Fenofibrate Intervention and Event Lowering in Diabetes study, which followed patients for around five years.
Researchers analysed blood samples from 216 participants in FIELD and compared those given 200 mg of co-micronised fenofibrate daily with those on placebo. According to the paper, FGF21 rose by 150.7% in the treatment group, while the placebo group recorded a smaller increase of 35.5%. Retinol-binding protein 4, or RBP4, also increased more sharply with fenofibrate, but adipocyte-fatty acid-binding protein did not change significantly.
The study suggests that fenofibrate’s effect on FGF21 is not simply a by-product of better lipid numbers. The researchers reported that the rise in FGF21 was independent of changes in lipids, blood sugar control and kidney markers, pointing instead to activation of the PPAR-alpha pathway, a receptor system that influences fat metabolism and energy use. The drug also lowered LDL cholesterol and apolipoprotein B over the study period.
The broader significance of the result is still uncertain. Other studies cited in PubMed have linked higher baseline FGF21 to an increased risk of cardiovascular events and microvascular complications in people with type 2 diabetes, which suggests the hormone may be a marker of underlying metabolic stress rather than a straightforward protective factor. That makes the fenofibrate findings interesting, but not proof that raising FGF21 itself improves outcomes.
FIELD itself is important context. The American College of Cardiology says the trial enrolled 9,795 people with type 2 diabetes and assessed cardiovascular outcomes over about five years. Separate analyses published in Diabetes Care and discussed by The American Journal of Cardiology reported around an 11% reduction in cardiovascular events with fenofibrate versus placebo, underscoring that the drug’s long-term effects have always been broader than simple lipid lowering.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
